Marie-Aude Khuong-Josses

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 364 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Brief Report

Sharon Walmsley, Axel Baumgarten, Juan Berenguer et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 219 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study

Frank A. Post, Graeme Moyle, Hans Jürgen Stellbrink et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 218 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

Michael Aboud, Chloe Orkin, Daniel Podzamczer et al. · The Lancet HIV · 2019 · 116 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Increased Risk of Serious Bacterial Infections Due to Maternal Immunosuppression in HIV-Exposed Uninfected Infants in a European Country

Clément Taron-Brocard, Jérôme Le Chenadec, Albert Faye et al. · Clinical Infectious Diseases · 2014 · 87 citations · Full text

Public Health, Infectious Diseases, Maternal Health +17